Market Cap | 63.42M | P/E | - | EPS this Y | 84.00% | Ern Qtrly Grth | - |
Income | -7.2M | Forward P/E | -2.45 | EPS next Y | -103.00% | 50D Avg Chg | -19.00% |
Sales | 2.84M | PEG | - | EPS past 5Y | - | 200D Avg Chg | -26.00% |
Dividend | N/A | Price/Book | 12.67 | EPS next 5Y | - | 52W High Chg | -48.00% |
Recommedations | 2.20 | Quick Ratio | 1.19 | Shares Outstanding | 8.55M | 52W Low Chg | 4.00% |
Insider Own | 1.62% | ROA | -71.42% | Shares Float | 8.41M | Beta | 1.39 |
Inst Own | 7.10% | ROE | - | Shares Shorted/Prior | 35.40K/32.72K | Price | 0.74 |
Gross Margin | - | Profit Margin | -253.60% | Avg. Volume | 273,682 | Target Price | 20.33 |
Oper. Margin | -32,799.12% | Earnings Date | Nov 7 | Volume | 380,742 | Change | 0.68% |
Daré Bioscience, Inc., a biopharmaceutical company, identifies, develops, and markets products for women's health in the United States. It develops therapies in the areas of contraception, reproductive health, menopause, fertility, and sexual and vaginal health. The company offers XACIATO for the treatment of bacterial vaginosis in female patients 12 years of age and older. It is developing Ovaprene, a hormone-free, monthly intravaginal contraceptive; Sildenafil Cream, a cream formulation of sildenafil for topical administration to the female genitalia on demand for the treatment of female sexual arousal disorder; DARE-HRT1 to treat moderate to-severe vasomotor symptoms in menopausal hormone therapy; DARE-VVA1 for the treatment of moderate-to-severe dyspareunia or pain during sexual intercourse; and DARE-CIN to treat cervical intraepithelial neoplasia and other human papillomavirus related pathologies. The company is also developing DARE-PDM1 for the treatment of primary dysmenorrhea; DARE-204 and DARE-214, an injectable formulations contraception of etonogestrel designed to provide contraception over 6-month and 12-month periods; DARE-FRT1, an intravaginal ring designed to deliver bio-identical progesterone for luteal phase support as part of an in vitro fertilization treatment plan; and DARE-PTB1 for the prevention of preterm birth. In addition, it is developing DARE-LARC1, a contraceptive implant delivering levonorgestrel with a woman-centered design that controlled contraceptive option; DARE-LBT, a novel hydrogel formulation for vaginal delivery of live biotherapeutics to support vaginal health; DARE-GML, a multi-target antimicrobial agent; DARE-RH1, a novel approach to non-hormonal contraception for men and women by targeting the CatSper ion channel; and DARE-PTB2 for the prevention and treatment of idiopathic preterm birth through inhibition of a stress response protein. Daré Bioscience, Inc. is headquartered in San Diego, California.
Jones Trading | Buy | Aug 16, 24 |
Maxim Group | Hold | Aug 14, 24 |
HC Wainwright & Co. | Buy | May 15, 24 |
Brookline Capital | Buy | May 15, 24 |
HC Wainwright & Co. | Buy | May 1, 24 |
Brookline Capital | Hold | Apr 17, 24 |
HC Wainwright & Co. | Buy | Apr 1, 24 |
HC Wainwright & Co. | Buy | Nov 10, 23 |
HC Wainwright & Co. | Buy | Aug 11, 23 |